Soluble endoglin has an anti-angiogenic effect and it has been shown that soluble endoglin levels are upregulated in pre-eclampsia, metabolic disorders, and cancer, although conflicting data have been reported (56, 58–60). This evidence concerns the gene ENG and Other metabolic disease.